← board
GNMSF
distress 1/10 · well-funded / low risk$274.500%today-22% from 52w high
Revenue
$896M
Liquidity
$1561M
Runway
—
Shares 1y
—
Price & events
-16.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-4.0%
1W
+9.8%
1M
+1.0%
3M
-16.1%
6M
+31.5%
1Y
+2.4%
2Y
-38.9%
5Y
-33.5%
All
Overview
- Volume
- 0
- 52 Week Range
- $209 – $352
- Float Shares
- 60.64M
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 40.93%
- Beta
- 0.69
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: — · 0 offerings/1y · 0 PIPEs
- 2025-07-15EFFECTshelf_effective
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- 2026-07-22GMAB stock gains as Genmab builds on Q1 2026 growth - Ad-hoc-news.de
- 2026-07-22Genmab stock trades steady as antibody revenue supports growth - Ad-hoc-news.de
- 2026-07-22Genmab stock holds after recent earnings and pipeline updates - Ad-hoc-news.de
- 2026-07-20Genmab stock holds on to late-stage data momentum - Ad-hoc-news.de
- 2026-07-18Genmab stock trades mixed as investors weigh Darzalex growth and upcoming earnings - Ad-hoc-news.de
- 2026-07-18What Makes Genmab A/S Sponsored ADR (GMAB) a Strong Momentum Stock: Buy Now? - MSN
- 2026-07-17Genmab stock trades steady as antibody pipeline and earnings support valuation - Ad-hoc-news.de
- 2026-07-15Genmab's Darzalex Generates $4.21 Billion in Q2 Net Trade Sales - marketscreener.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.